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Abstract
Background: South Africa has one of the highest incidences of multidrug-resistant tuberculosis (MDR-TB) in the
world. Concomitantly, aminoglycosides are commonly used in this country as a treatment against MDR-TB. To
date, at least five mutations are known to confer susceptibility to aminoglycoside-induced hearing loss. The aim
of the present study was to develop a rapid screening method to determine whether these mutations are present
in the South African population.
Methods: A multiplex method using the SNaPshot technique was used to screen for five mutations in the MT-
RNR1 gene: A1555G, C1494T, T1095C, 961delT+C(n) and A827G. A total of 204 South African control samples,
comprising 98 Mixed ancestry and 106 Black individuals were screened for the presence of the five mutations.
Results: A robust, cost-effective method was developed that detected the presence of all five sequence variants
simultaneously. In this pilot study, the A1555G mutation was identified at a frequency of 0.9% in the Black control
samples. The 961delT+C(n) variant was present in 6.6% of the Black controls and 2% of the Mixed ancestry
controls. The T1095C, C1494T and A827G variants were not identified in any of the study participants.
Conclusion: The frequency of 0.9% for the A1555G mutation in the Black population in South Africa is of
concern given the high incidence of MDR-TB in this particular ethnic group. Future larger studies are warranted
to determine the true frequencies of the aminoglycoside deafness mutations in the general South African
population. The high frequencies of the 961delT+C(n) variant observed in the controls suggest that this change
is a common non-pathogenic polymorphism. This genetic method facilitates the identification of individuals at high
risk of developing hearing loss prior to the start of aminoglycoside therapy. This is important in a low-resource
country like South Africa where, despite their adverse side-effects, aminoglycosides will continue to be used
routinely and are accompanied with very limited or no audiological monitoring.
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South Africa is rated 4th among the 22 high-burden tuber-
culosis (TB) countries by the World Health Organisation
(WHO) [1]. A recent study showed that eight of the nine
South African provinces (no data was available for the 9th
province) have an estimated incidence of greater than
three per 100,000 of the population for multidrug-resist-
ant tuberculosis (MDR-TB) [2]. In the Western Cape Prov-
ince, the estimated incidence for MDR-TB is 8.39 per
100,000. Aminoglycoside antibiotics such as kanamycin
and amikacin are part of the WHO's recommended treat-
ment regimen for MDR-TB and streptomycin is used for
re-treatment TB cases [3]. In South Africa, aminoglyco-
sides are routinely used to treat severe Gram-negative bac-
terial infections but their usage is on the increase because
of the high incidence of re-treatment TB and MDR-TB
cases. These drugs have well-documented adverse reac-
tions such as ototoxicity and nephrotoxicity. The nephro-
toxicity is usually reversible but the ototoxicity, which is
most likely due to damage to the sensory hair cells and the
stria vascularis in the cochlea, is permanent [4].
In China, where there is also widespread use of aminogly-
cosides, the incidence of ototoxicity has been well docu-
mented. In a district of Shanghai, the cause of hearing loss
could be traced to aminoglycoside usage in approximately
22% of all deaf mute individuals [5]. Although some of
the earliest reports on this condition came from South
Africa [6,7], no data on the incidence of aminoglycoside-
induced deafness has ever been documented for this
country.
To date, at least five different homoplasmic mutations in
the mitochondrial gene encoding 12S rRNA (MT-RNR1)
have been found to predispose individuals to irreversible
hearing loss if they are treated with aminoglycoside anti-
biotics. These include A1555G [8], 961delT+C(n) [9],
T1095C [10], C1494T [11] and A827G [12]. The A1555G
mutation, which was the first one to be described, is the
most common variant and has been reported in diverse
populations worldwide [13]. Individuals harbouring
A1555G can develop hearing loss even in the absence of
aminoglycoside exposure [14]. Various methods have
been used to screen for these mutations including allele-
specific polymerase chain reaction (PCR) [15], DNA
sequencing [16], PCR-restriction fragment length poly-
morphism (PCR-RFLP) analysis [14,16] and allele-spe-
cific oligonucleotide hybridisation (ASO) [17]. All these
methods are limiting in that they can detect only one
mutation at a time and are not amenable to multiplexing.
In the present study we aimed to develop a cost-effective
multiplex genetic screening method in order to determine
whether these five sequence variants are present in the
South African population. Given that in South Africa
aminoglycosides are commonly used, and that their usage
will be on the increase in the near future to combat the ris-
ing MDR-TB epidemic it is important to determine the
prevalence of these mutations. A method is needed to
identify individuals or particular South African ethnic
groups that are at increased risk of developing hearing loss
prior to them starting aminoglycoside therapy.
Methods
Study participants
The study was approved by the Committee for Human
Research at Stellenbosch University, South Africa (Proto-
col number: N05/09/165). Following informed written
consent, blood samples from 204 controls from the West-
ern Cape Province, consisting of 98 Mixed ancestry indi-
viduals and 106 Black individuals, were collected for
genetic analysis. Only these two ethnic groups were inves-
tigated in the present study since the highest incidence of
MDR-TB in this country occurs in these two sub-popula-
tions. South African Mixed ancestry represents predomi-
nantly an admixture of indigenous African populations,
European immigrants from Western Europe and inden-
tured labourers from Madagascar, the Malaysian archipel-
ago and India [18].
SNaPshot Analysis
Genomic DNA was extracted from blood samples col-
lected from the study participants using established meth-
ods. PCR primers spanning the MT-RNR1 gene were
designed using Primer3 software [19].
The SNaPshot technique (Applied Biosystems, Foster City,
USA) is a method used specifically to genotype single
nucleotide polymorphisms (SNPs). It involves PCR
amplification of a region of interest, purification of the
product and annealing of a SNaPshot primer that ends
one nucleotide 5' of a known SNP. A single base extension
reaction is then performed in the presence of the four flu-
orescently-labelled dideoxynucleotide triphosphates
(ddNTPs). Upon excitation with a laser, the different flu-
orescent dyes emit a colour which is specific for each
ddNTP i.e. green for A, blue for G, black for C and red for
T. Multiple SNPs (up to 12) can be interrogated in a single
SNaPshot reaction with the SNaPshot primers for the dif-
ferent SNPs varying in length. Therefore, following elec-
trophoresis, each SNP's genotype is determined by both
the position (size) of the peak as well as by the colour of
the emitted fluorescence. In the case of homoplasmic
mutations (such at the ones described in the present
study), each variant's genotype is represented by a single
peak e.g. for C1494T either a black peak or a red peak is
present, for the C or the T allele, respectively. Initially,
each mutation was analysed separately to establish the
intervals for the observed peak locations (bins) for each
allele. Thereafter, the five variants were multiplexed andPage 2 of 9
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length and orientation of the five SNaPshot primers
underwent a series of redesigning and optimisation exper-
iments until adequate separation of all the alleles repre-
senting the five different loci was achieved. The
GeneMapper software (version 3.7; Applied Biosystems)
was used to set up the bins for each allele for the muta-
tions investigated and was also used for automated allele
scoring and quality checking. Small non-specific peaks
that were either below a certain threshold peak height or
that did not fall into the specific bins were disregarded by
the GeneMapper software and not genotyped.
The PCR and SNaPshot primers designed for the study are
provided in Table 1. PCR reactions were performed in 50
μl reactions on a 2720 Thermal Cycler (Applied Biosys-
tems, USA). The PCR cycling conditions comprised of an
initial denaturation step of 94°C for 5 min, 30 cycles of
denaturation at 94°C for 30 sec, annealing at 55°C for 30
sec, extension at 72°C for 45 sec, and a final extension
step of 72°C for 7 min. Following PCR, 3 μl of the PCR
product was incubated with 1 unit of shrimp alkaline
phosphatase (SAP; Promega) and 0.2 units of Exo I (AEC
Amersham) for 60 min at 37°C, followed by 30 min at
75°C for enzyme inactivation.
The SNaPshot extension reactions were carried out in a
final volume of 10 μl containing 3 μl of purified PCR
product, 3 μl of SNaPshot Ready Reaction Mix (ABI Prism
SNaPshot Multiplex Kit) and 1.67 μl of a mixture of each
of the five SNaPshot primers (each at 1.8 μM, except the
primer for A1555G which was 2.9 μM). The cycling con-
ditions were 27 cycles of 96°C for 10 sec, 50°C for 5 sec
and 60°C for 30 sec. After primer extension, the unincor-
porated fluorescently labelled ddNTPs were removed by
adding 1 unit of SAP and incubating for 60 min at 37°C
followed by 30 min at 75°C for enzyme deactivation. One
μl of each SNaPshot reaction, 0.5 μl Liz 120 size standard
(Applied Biosystems) and 9 μl of HiDi formamide was
loaded on an ABI 3130 × l Genetic Analyzer (Applied Bio-
systems) and electrophoresed using POP 7 polymer. All
samples were genotyped using the GeneMapper software.
Direct sequencing of selected samples was performed
using the BigDye Terminator Sequence Ready Reaction kit
version 3.1 (Applied Biosystems) and run on a 3130 × l
Genetic Analyzer. The initial analysis was performed using
Sequencing Analysis software (version 5.3.1) and BioEdit
software (version 7.0.1) was used for interpretation of the
sequencing electropherograms [20].
Sequence alignments
To investigate the sequence conservation of MT-RNR1,
multiple sequence alignments were performed using the
Clustal W program (version 1.83). Sequences from the
following six species were obtained from NCBI: human
(NC_001807), chimp (NC_001643), gorilla
(NC_001645), mouse (NC_005089), rat (NC_001665),
dog (NC_002008) and cow (NC_006853).
Results
A method for the simultaneous detection of five of the
known aminoglycoside-induced deafness mutations has
been developed in this study (Figures 1 and 2). PCR prim-
ers were designed that amplified the entire MT-RNR1 gene
in a 1,124 bp PCR fragment for SNaPshot analysis. Using
ABI GeneMapper software, bins were assigned at each of
the five loci which facilitated high-throughput allele scor-
ing and quality checking. At least one positive control for
the mutant allele at each of the five loci was included in
the analysis and was correctly genotyped in all runs. Fur-
thermore, direct sequencing was performed on selected
samples to verify the SNaPshot results and there was a
100% concordance.
The A1555G mutation was identified in one of the 106
Black control samples and in none of the Mixed ancestry
controls (Table 2). This represents an observed frequency
of 0.9% (95% CI 0.17% to 5.15%) for the A1555G muta-
tion in the Black population in South Africa which is of
concern given the high incidence of MDR-TB in this par-
Table 1: Primers used for PCR amplification and SNaPshot extension reactions.
Primer sequences (5'-3')
PCR primers For: caa cca aac ccc aaa gac ac
Rev: gct cag agc ggt caa gtt aag
Variant Primer sequences (5'-3') Orientation
SNaPshot primers
A1555G ttg gca ttt ata tag agg ag forward
C1494T cgt aca cac cgc ccg tca c forward
T1095C ctg gga tta gat acc cca cta tgc t forward
961delT+C(n) aca ggt gag ttt tag ctt tat tgg gg reverse
A827G gct tag tta aac ttt cgt ttg ttg cta aag g reversePage 3 of 9
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established aminoglycoside-induced deafness associated
mutation and the A1555 allele is evolutionarily conserved
across diverse species and is embedded in a conserved
region of the gene (Figure 3).
The 961delT+C(n) variant was identified at a relatively
high frequency in this South African group of study partic-
ipants. This variant was unambiguously detected using
the SNaPshot technique. All 961delT+C(n)-positive sam-
ples were verified with sequencing to not be the other pos-
sible alleles at this locus including the 961insC or T961G
variants (Figure 4). The 961delT+C(n) variant was
observed in 6.6% of the Black controls and 2% of the
Mixed ancestry controls (Table 2). These results indicate
that the 961delT+C(n) variant may possibly be a common
non-pathogenic polymorphism in the MT-RNR1 gene.
This observation is corroborated by the fact that the T961
SNaPshot analysis of the five mutations [C1494T, T1095C, A1555G, 961delT+C(n) and A827G]Figure 1
SNaPshot analysis of the five mutations [C1494T, T1095C, A1555G, 961delT+C(n) and A827G]. Peaks are 
shown that represent wild-type alleles, for one individual, at all five loci. The smaller non-specific peaks in the figure are all 
either below a certain threshold peak height value or do not fall into specific bins and are therefore not genotyped by the Gen-
eMapper software. * The SNaPshot extension primers for 961 delT+C(n) and A827G are in the reverse orientation. In the 
SNaPshot figure, the genotypes are represented as follows: For C1494T, either a black peak (representing the C allele) or a 
red peak (T allele) is present, in their respective bin positions. For T1095C, either a red peak (T allele) or a black peak (C 
allele) is present, in their respective bin positions. For A1555G, either a green peak (A allele) or a blue peak (G allele) is 
present, in their respective bin positions. For 961delT+C(n) (as the primer anneals to the reverse strand), either a green peak 
(A allele; T on forward strand) or a blue peak (G allele; C on forward strand) is present, in their respective bin positions. For 
A827G (as the primer anneals to the reverse strand), either a red peak (T allele; A on forward strand) or a black peak (C allele; 
G on forward strand) is present, in their respective bin positions.
Locus:    1494                  1095  1555     961        827
Allele present:      C    T        A   T*          A*Page 4 of 9
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served (Figure 3). The T1095C, C1494T and A827G vari-
ants were not identified in any of the study participants.
The method described in the present study was specifi-
cally designed and optimised to detect homoplasmic
mutations, since, in the majority of published reports, the
five mutations [A1555G, C1494T, T1095C,
961delT+C(n) and A827G] are present in the homoplas-
mic state. The SNaPshot method has, however, previously
been shown to be a sensitive and reproducible method for
the detection of heteroplasmic mutations in different tis-
sues [21] but since no heteroplasmic mutations were
detected in the present study, and as no heteroplasmic
SNaPshot analysis of an individual who harbours wild-type alleles at four of the loci and the mutant allele (delT) for 961delT+C(n)Figure 2
SNaPshot analysis of an individual who harbours wild-type alleles at four of the loci and the mutant allele 
(delT) for 961delT+C(n). The five peaks each represent an allele as described in detail in the legend to Figure 1. * The 
SNaPshot extension primers for 961 delT+C(n) and A827G are in the reverse orientation.
Locus:                1494                    1095  1555     961 827
Allele present:      C                          T       A       C*                  A*
Table 2: Frequency of the five aminoglycoside-induced deafness mutations in two South African populations.
Variants in MT-RNR1
Study participants C1494T T1095C A1555G 961delT+C(n) A827G
Black controls n = 106 0 0 1 (0.9%) 7 (6.6%) 0
Mixed ancestry controls n = 98 0 0 0 2 (2.0%) 0
TOTAL 0 0 1 9 0Page 5 of 9
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Sequence alignments of the MT-RNR1 gene across diverse species indicating that the A1555, A827, T1095 and C1494 alleles are all evolutionarily conserved but that the T allele at 961 is notFig re 3
Sequence alignments of the MT-RNR1 gene across diverse species indicating that the A1555, A827, T1095 and 
C1494 alleles are all evolutionarily conserved but that the T allele at 961 is not.
A1555G
Human           TATATAGAGGAGACAAGTCGTAACA
Chimp           TATATAGAGGAGATAAGTCGTAACA 
Gorilla         TATATAGAGGAGATAAGTCGTAACA 
Mouse           TAT-GAGAGGAGATAAGTCGTAACA 
Rat             TAT-GAGAGGAGATAAGTCGTAACA 
Dog             ACACAAGAGGAGACAAGTCGTAACA 
Cow             ACATGAGAGGAGACAAGTCGTAACA 
                     ******** *********** 
A827G
Human           CAGCAGTGATTAACCTTTAGCAATA 
Chimp           CAGCAGTGATAAACCTTTAGCAATA 
Gorilla         CAGCAGTGATTAACCTTTAGCAATA 
Mouse           CAGCAGTGATAAATATTAAGCAATA 
Rat             CAGCAGTGATAAATATTAAGCAATG 
Dog             CAGCAGTGATAAAAATTAAGCCATA 
Cow             CAGCAGTGACAAAAATTAAGCCATA 
                *********  **  ** *** ** 
961delT+C(n)
Human           TTAGATCACCCCCTCCCCAATAAAGCT 
Chimp           TTAGATCA----CCCCCCCATAAAGCT 
Gorilla         TTAGATCA----ATCCCCAATAAAGCT 
Mouse           AACTATAA---ATAAATAAATAGAATT 
Rat             AACTATAA---ATCTCATAATAGAATT 
Dog             CAAGATAC----TTTTACACTAAAGTT 
Cow             AAAGCACC----ATACCAAATAGGGTT 
                                    **    *
T1095C
Human           CCCCACTATGCTTAGCCCTAAACCT 
Chimp           CCCCACTATGCTTAGCCCTAAACTT 
Gorilla         CCCCACTATGCCTAGCCCTAAACTT 
Mouse           CCCCACTATGCTTAGCCATAAACCT 
Rat             CCCCACTATGCTTAGCCCTAAACCT 
Dog             CCCCACTATGCTTAGCCCTAAACAT 
Cow             CCCCACTATGCTTAGCCCTAAACAC 
              *********** ***** *****
C1494T
Human           ACCGCCCGTCACCCTCCTCAAGT-A 
Chimp           ACCGCCCGTCACCCTCCTCAAGT-A 
Gorilla         ACCGCCCGTCACCCTCCTCAAGT-A 
Mouse           ACCGCCCGTCACCCTCCTCAAATTA 
Rat             ACCGCCCGTCACCCTCCTCAAATTA 
Dog             ACCGCCCGTCACCCTCCTCAAGT-A 
Cow             ACCGCCCGTCACCCTCCTCAAAT-A 
                ********************* * *
BMC Medical Genetics 2009, 10:2 http://www.biomedcentral.com/1471-2350/10/2positive controls were available for testing, we cannot at
this stage, comment on how well suited our method is for
the detection of heteroplasmic mutations.
Discussion
We have successfully developed a rapid, robust and cost-
effective method for the screening of five of the known
aminoglycoside-induced deafness mutations. The SNaP-
shot technique is particularly well-suited for the screening
of mitochondrial DNA variants for the following reasons:
i) the short intron-less mitochondrial genes means that
the entire gene can be PCR-amplified and screened in a
single PCR fragment and ii) homoplasmic mutations
(such as the ones investigated in the present study) are
represented as a single peak at each locus which simplifies
the analysis. This method is also less labour-intensive and
less prone to false positives compared to the other meth-
ods reported to date. In one study using PCR-RFLP and
the enzyme, Alw26I to screen for A1555G, a false positive
was detected: DNA sequencing revealed that the patient
had in fact a T1556C variant, which also disrupts the
Alw26I site [22]. In another study using ASO, the authors
reported that this method was not effective for detection
of the 961delT+C(n) variant [17]. In a low-resource coun-
try like South Africa, a typical alternative method used for
SNP genotyping would be PCR-RFLP. An estimated cost
comparison between the two methods (including DNA
extraction) is ~$16 per sample for the SNaPshot method
versus~$30 per sample for the PCR-RFLP method (using
an exchange rate of $1 = 10.39 ZAR).
This is the first report on the frequency of aminoglycoside-
induced deafness mutations in South African sub-popula-
tions. In the present pilot study, the A1555G mutation
was present at a frequency of 0.9% in the South African
Black control group. Further studies on larger numbers of
study participants are needed to determine the true fre-
quency of A1555G in this particular ethnic group but if
the frequency is shown to be ≥ 1% this has important
implications given the high incidence of TB and MDR-TB
in this group. The A1555G has been found to be very
uncommon in the general populations worldwide. It was
found in 0.48% (1/206) [15], 0.09% (1/1,161) [17] and
0% (0/1,042) [23] of the general New Zealand, American
and Argentinean populations, respectively.
The 961delT+Cn variant was detected at high frequencies
in the study participants: 6.6% of the Black controls and
2% of the Mixed ancestry controls. Other studies have
found this variant at a high frequency of controls and they
also questioned the pathogenicity of this variant [17,24].
Furthermore, all the variants with the notable exception of
961delT+C(n) are evolutionarily conserved from man to
cow which indicates their functional significance and that
961delT+Cn is likely to be a non-functional polymor-
phism. In a recent study it was shown that both A1555G
and C1494T decrease the accuracy of translation in the
mitochondrion and rendered the ribosomal decoding site
hyper-susceptible to aminoglycosides [25]. Similar stud-
ies on 961delT+C(n), A827G and T1095C are needed to
prove the pathogenicity of these variants and their possi-
ble effects on the functioning of the mitochondria. The
T1095C, C1494T and A827G were not found in any of the
study participants in the present study.
Future studies are warranted to determine the true fre-
quencies of the various aminoglycoside deafness muta-
tions in the general South African population and also
whether certain aminoglycosides are more ototoxic than
others. Despite their adverse effects, aminoglycosides are
Representative sequencing results confirming the presence of the 961delT+C(n) variant as detected by SNaPshot analysisFigure 4
Representative sequencing results confirming the presence of the 961delT+C(n) variant as detected by SNaP-
shot analysis.
T deleted and a series of C’s insertedPage 7 of 9
(page number not for citation purposes)
BMC Medical Genetics 2009, 10:2 http://www.biomedcentral.com/1471-2350/10/2currently and in the future will continue to be used in
developing countries like South Africa for re-treatment TB
and MDR-TB where cost considerations are a major factor.
South Africa is therefore an ideal setting to study this par-
ticular problem. In MDR-TB infections aminoglycoside
administration is unavoidable and often has to be contin-
ued even though the patient experiences hearing loss.
However, possible strategies to minimise the progression
of cochlear and vestibular damage are: to identify high
risk individuals who are mutation-positive and in these
individuals to reduce the therapy time, to avoid drugs
with synergistic ototoxic effects and to perform regular
audiological monitoring throughout treatment. Audio-
logic testing facilities are virtually non-existent in many
countries in Africa and elsewhere in the developing world.
Identifying and only testing those patients at-risk of
aminoglycoside induced ototoxicity would lead to more
efficient use of limited audiologic facilities. It is also
imperative that all maternal relatives, since these are mito-
chondrial mutations, of mutation-positive individuals
should be counselled about their propensity to develop
irreversible hearing impairment if they are treated with
aminoglycosides.
Conclusion
In the present study we have developed a cost-effective
method using the SNaPshot technique that in a single
reaction detects five of the known mutations associated
with aminoglycoside-induced hearing loss. This test
would facilitate the detection of susceptible individuals
prior to the start of their aminoglycoside therapy and so
potentially could lower the incidence of this type of deaf-
ness.
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